20 completed, 3 terminated, 2 recruiting, 1 no longer available. 19 Phase 2, 14 Phase 1, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 19 | Completed 15, Terminated 3, Recruiting 1 |
| Phase 1 | 14 | Completed 12, Recruiting 1, Terminated 1 |
| Phase 3 | 1 | Completed 1 |
Follow carotuximab: new trials by email Literature Review of carotuximab trials Research Report on carotuximab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study of AR Suppression With Carotuximab in Metastatic, Castration-Resistant Prostate Canc AR Blockade, Carotuximab - Castration-resistant Prostate Cancer | Phase 2 | Recruiting | Edwin Posadas, MD | 116 | 2023-12-27 | 2026-10-05 |
| Study of Osimertinib With Carotuximab in Advanced, EGFR-mutated Non-Small Cell Lung Cancer Osimertinib, Carotuximab - Non Small Cell Lung Cancer, Lung Cancer | Phase 1 | Recruiting | Karen Reckamp, MD, MS | 60 | 2023-09-15 | 2026-08-06 |
| Study of TRC105 With Abiraterone and With Enzalutamide in Prostate Cancer Patients Progressing on Therapy TRC105, Abiraterone, Enzalutamide - Prostate Cancer | Phase 2 | Completed | Cedars-Sinai Medical Center | 11 | 2018-03-05 | 2020-12-30 |
| Study of Carotuximab (TRC105) Plus Nivolumab in Patients With Metastatic NSCLC Carotuximab (TRC105), OPDIVO - Carcinoma, Non-Small-Cell Lung | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 11 | 2017-11-09 | 2020-06-24 |
| Trial of TRC105 and Pazopanib Versus Pazopanib Alone in Patients With Advanced Angiosarcoma TRC105, Votrient - Advanced Angiosarcoma | Phase 3 | Completed | Tracon Pharmaceuticals Inc. | 128 | 2017-02-13 | 2020-05-12 |
| Trial of TRC105 and Sorafenib in Patients With HCC Carotuximab (TRC105), Sorafenib - Hepatocellular Carcinoma | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 27 | 2016-11-01 | 2020-07-17 |
| Study of TRC105 and Bevacizumab in Patients With Refractory Gestational Trophoblastic Neoplasia (GTN) TRC105, Bevacizumab - Gestational Trophoblastic Neoplasia, Choriocarcinoma | Phase 2 | Terminated | Tracon Pharmaceuticals Inc. | 3 | 2016-03-01 | 2019-07-23 |
| A Study of TRC105 in Combination With Paclitaxel/Carboplatin and Bevacizumab in Non-Squamous Cell Lung Cancer TRC105 - Lung Cancer | Phase 1 | Completed | University of Alabama at Birmingham | 16 | 2015-11-02 | 2021-06-28 |
| A Phase I/II Safety, Tolerability, Immunogenicity, and Bioactivity Study of DE-122 Injectable Solution for Refractory Exudative Age-related Macular Degeneration 0.5 mg of DE-122, 1.0 mg of DE-122, 2.0 mg of DE-122 - Age-Related Macular Degeneration | Phase 1 / Phase 2 | Completed | Santen Inc. | 12 | 2015-09-16 | 2020-01-14 |
| Study of TRC105 + Paclitaxel/Carboplatin and Bevacizumab in Patients With NSCLC TRC105 - Non Small Cell Lung Cancer | Phase 1 | Completed | Tracon Pharmaceuticals Inc. | 15 | 2015-09-01 | 2019-10-28 |
| Combination of Letrozole, Everolimus and TRC105 in Postmenopausal Women With Hormone-Receptor Positive and Her2 Negative Breast Cancer Letrozole, Everolimus, TRC105 - Breast Cancer | Phase 1 / Phase 2 | Completed | University of Alabama at Birmingham | 15 | 2015-02-01 | 2026-02-06 |
| TRC105 Combined With Standard-dose Bevacizumab for Two Patients With Metastatic And Refractory Choriocarcinoma TRC105, Bevacizumab - Choriocarcinoma | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 2 | 2015-01-01 | 2019-06-11 |
| A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma TRC105 and Pazopanib - Advanced Soft Tissue Sarcoma | Phase 1 / Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 111 | 2013-12-10 | 2020-05-20 |
| Randomized Phase 2 Trial of Axitinib and TRC105 Versus Axitinib Alone in Patients Renal Cell Carcinoma TRC105 and Axitinib, Axitinib - Renal Cell Carcinoma | Phase 1 / Phase 2 | Terminated | Tracon Pharmaceuticals Inc. | 173 | 2013-03-08 | 2020-10-19 |
| TRC105 for Recurrent Glioblastoma TRC105 - Glioblastoma Multiforme | Phase 2 | Terminated | National Cancer Institute (NCI) | 2 | 2012-12-01 | 2015-10-07 |
| Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis - Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma | Phase 1 / Phase 2 | Completed | National Cancer Institute (NCI) | 116 | 2012-11-01 | 2018-05-23 |
| Bevacizumab With or Without TRC105 in Treating Patients With Metastatic Kidney Cancer Anti-Endoglin Chimeric Monoclonal Antibody TRC105, Bevacizumab, Laboratory Biomarker Analysis - Clear Cell Renal Cell Carcinoma, Recurrent Renal Cell Carcinoma | Phase 2 | Completed | National Cancer Institute (NCI) | 59 | 2012-11-01 | 2018-08-28 |
| A Phase 2 Evaluation of TRC105 In Combination With Bevacizumab in Patients With Glioblastoma TRC105, Bevacizumab - Glioblastoma, Glioblastoma Multiforme | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 22 | 2012-05-01 | 2019-06-12 |
| Evaluation of TRC105 in the Treatment of Recurrent Ovarian, Fallopian Tube, or Primary Peritoneal Carcinoma Carotuximab (TRC105) - Recurrent Ovarian Cancer, Fallopian Tube Carcinoma | Phase 2 | Completed | Tracon Pharmaceuticals Inc. | 23 | 2011-07-01 | 2019-03-05 |
| TRC105 for Liver Cancer That Has Not Responded to Sorafenib TRC105 - Hepatocellular Carcinoma, Hepatocellular Cancer | Phase 2 | Completed | National Cancer Institute (NCI) | 11 | 2011-06-22 | 2017-07-28 |
Showing 20 of 26. Sign in to see all of them.
Carcinoma, Hepatocellular (3) · Carcinoma, Non-Small-Cell Lung (3) · Glioblastoma (3) · Prostatic Neoplasms (3) · Breast Neoplasms (2) · Carcinoma, Renal Cell (2) · Choriocarcinoma (2) · Glioma (2) · Hemangiosarcoma (2) · Liver Neoplasms (2) · Lung Neoplasms (2) · Adenoma, Liver Cell (1) · Astrocytoma (1) · Brain Neoplasms (1) · Carcinoma, Transitional Cell (1)
Tracon Pharmaceuticals Inc. (13) · National Cancer Institute (NCI) (7) · University of Alabama at Birmingham (2) · Cedars-Sinai Medical Center (1) · Edwin Posadas, MD (1) · Karen Reckamp, MD, MS (1) · Santen Inc. (1)
United States (25) · United Kingdom (2) · Australia (1) · Austria (1) · Czechia (1) · France (1) · Germany (1) · Hungary (1) · Italy (1) · Poland (1) · Spain (1) · Taiwan (1)
Charles Theuer, MD (5) · Charles Theuer, MD PhD (3) · Charles Theuer, MD, PhD (3) · Charles P Theuer, MD (2) · Edwin Posadas, MD FACP (2) · Tim F Greten, M.D. (2) · Andrea B Apolo, M.D. (1) · Erica Stringer-Reasor, M.D. (1) · Erica Stringer-Reasor, MD (1) · Evanthia Galanis (1) · Francisco Robert, MD (1) · Joohee Sul, M.D. (1) · Karen Reckamp, MD, MS (1) · Tanya Dorff (1) · William L Dahut, M.D. (1)
PMID 27328856, PMID 30190302, PMID 30357394, PMID 35357396, PMID 36735117
N01CM00038 (1), N01CM00039 (1), N01CM00071 (1), N01CM00099 (1), P30CA033572 (1), U10CA025224 (1), U10CA180821 (1)